P/OSPeptideOS evidence & status map
OPEN SOURCE MEDICINE FOUNDATIONLast reviewed 2026-10-10No dosing · no vendors · no advicesource file

← All compounds · evidence tier first, by design

Evidence tier for each claimed use · ← established · unknown →
UseE1E2E3E4E5E6E7E8
E1 Postmenopausal osteoporosis (fracture prevention)E1
E2 Osteoporosis in menE2
E2 Glucocorticoid-induced osteoporosisE2
E3 Acceleration of fracture healing (off-label claim)E3
Class A · Approved

Teriparatide

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF

Identical to the 34 N-terminal residues of the 84-residue human parathyroid hormone; Forteo is produced in a recombinant Escherichia coli strain (US label, section 11).

Also: PTH(1-34), rhPTH(1-34), Parathyroid hormone (1-34) · Brands: Forteo, Forsteo, Bonsity, Movymia, Terrosa, Livogiva, Sondelbay, Kauliv, Teriparatide SUN, Zandoriah, Osnuvo

A 34-amino-acid fragment of human parathyroid hormone, the region responsible for its biological activity. It is an approved prescription medicine for osteoporosis in the US, EU, Canada and Japan, sold originally as Forteo (Forsteo in the EU) and now also as several follow-on and biosimilar products. Unlike most osteoporosis drugs, which slow bone breakdown, it is classed as a bone-forming (anabolic) agent. Regulatory status in the UK, Australia and China was not verified for this record.

  • US A approved
  • EU A approved
  • UK ? not verified
  • CA A approved
  • AU ? not verified
  • JP A approved
  • CN ? not verified

01Regulatory status, by jurisdiction

JurisdictionStatusDetail and primary source
USApprovedApproved under NDA 021318 (Forteo, Eli Lilly; original approval 26 Nov 2002). Drugs@FDA also lists Bonsity (NDA 211939), a teriparatide product under NDA 218771, and generic teriparatide ANDAs (Teva, Apotex, Amphastar). Label indications: postmenopausal osteoporosis at high fracture risk, increasing bone mass in men with primary or hypogonadal osteoporosis, and glucocorticoid-associated osteoporosis.
“FORTEO is a parathyroid hormone analog, (PTH 1-34), indicated for:”
FORTEO (teriparatide injection) Prescribing Information, revised 08/2026 · retrieved 2026-10-10
EUApprovedCentrally authorised as Forsteo since 10 June 2003. The EMA medicines dataset also lists authorised teriparatide products Movymia, Terrosa, Livogiva, Sondelbay, Kauliv, Teriparatide SUN and Zandoriah; Qutavina was withdrawn after authorisation.
“This medicine is authorised for use in the European Union”
Forsteo | European Medicines Agency (EMA) · retrieved 2026-10-10
CAApprovedHealth Canada Drug Product Database lists teriparatide products including TEVA-TERIPARATIDE INJECTION (DIN 02486423, Marketed), OSNUVO (DIN 02495589, Marketed) and APO-TERIPARATIDE INJECTION (DIN 02498804, Marketed). FORTEO (DIN 02254689) is listed as Cancelled Post Market (24 Feb 2026).
“Current status: Marketed”
Drug Product Database: TEVA-TERIPARATIDE INJECTION · retrieved 2026-10-10
JPApprovedPMDA's English review-report index lists Forteo, teriparatide (genetical recombination), approved July 2010. Other Japanese teriparatide products were not verified for this record.
“Forteo Teriparatide (genetical recombination) July 2010”
Review Reports: Drugs | PMDA · retrieved 2026-10-10
UK AU CNNot yet verified from a primary source. No status is shown rather than an unsourced one.

Sport (WADA): Not prohibited. Not named on the Prohibited List. As an approved medicine it also falls outside class S0, which covers only substances without current regulatory approval: “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use” WADA source

02What the human evidence shows

E1

Postmenopausal osteoporosis (fracture prevention)

2published human RCTs
n/cpublished human trials
182registered studies
63with posted results

n/c: not counted here; see the cited review.

Two large randomised controlled trials with fracture endpoints support this approved indication. In the pivotal placebo-controlled trial of 1,637 postmenopausal women with prior vertebral fracture, teriparatide reduced new vertebral and nonvertebral fragility fractures and increased bone mineral density. In VERO, a double-blind trial of 1,360 women with severe osteoporosis, new vertebral fractures were less frequent with teriparatide than with the active comparator risedronate. Reduction of hip fracture has not been demonstrated (EMA product overview).

  • [1] Reduced new vertebral and nonvertebral fragility fractures versus placebo in postmenopausal women with prior vertebral fracture
  • [2] New vertebral fractures in 5.4% with teriparatide versus 12.0% with risedronate over 24 months in women with severe osteoporosis

Registered-study counts: ClinicalTrials.gov intervention search “teriparatide”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E2

Osteoporosis in men

1published human RCTs
n/cpublished human trials
5registered studies
2with posted results

n/c: not counted here; see the cited review.

One randomised placebo-controlled trial in 437 men with low bone density showed increased spine and hip bone mineral density. Its endpoint was bone density, not fracture; the trial was stopped early, after a median of about 11 months, because of the rat osteosarcoma finding. The US label accordingly describes the male indication as increasing bone mass, not reducing fractures.

  • [3] Increased lumbar spine and femoral neck bone mineral density versus placebo in men with osteoporosis

Registered-study counts: ClinicalTrials.gov intervention search “teriparatide AND male osteoporosis”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E2

Glucocorticoid-induced osteoporosis

1published human RCTs
n/cpublished human trials
5registered studies
3with posted results

n/c: not counted here; see the cited review.

One randomised double-blind trial of 428 adults on long-term glucocorticoids compared teriparatide with alendronate. Lumbar spine bone mineral density rose more with teriparatide (primary endpoint), and fewer new vertebral fractures were recorded in the teriparatide group (a secondary outcome); serum calcium elevations were more common with teriparatide. No placebo-controlled fracture trial exists in this population.

  • [4] Greater increase in lumbar spine bone mineral density with teriparatide than with alendronate in glucocorticoid-treated adults

Registered-study counts: ClinicalTrials.gov intervention search “teriparatide AND glucocorticoid”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E3

Acceleration of fracture healing (off-label claim)

No human trial of any design has been published for this use.

0published human RCTs
n/cpublished human trials
14registered studies
4with posted results

n/c: not counted here; see the cited review.

Not an approved use. In a randomised double-blind trial of 102 postmenopausal women with distal radius fractures, the prespecified primary comparison (higher-dose teriparatide versus placebo) showed no difference in time to radiographic healing; a shorter healing time in the lower-dose arm came from a post hoc analysis that the authors said should be interpreted with caution. No adequately powered trial has shown faster fracture healing.

  • [5] Primary hypothesis (shorter time to cortical bridging with the higher-dose arm versus placebo) not supported in women with distal radial fractures

Registered-study counts: ClinicalTrials.gov intervention search “teriparatide AND fracture healing”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

Key registered trials

NCTTitle (as registered)PhaseStatus
NCT00670501Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis3Completed
NCT01709110VERtebral Fracture Treatment Comparisons in Osteoporotic Women4Completed
NCT00051558Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis3Completed

03Safety signals

S1Large long-term human exposure (post-marketing surveillance)
  • Osteosarcoma in rats [6]
    Long-term treatment of F344 rats produced bone neoplasms, including osteosarcoma, with incidence dependent on dose and treatment duration. The US label retains an osteosarcoma warning and states there are limited data on risk beyond 2 years of use.
  • Osteosarcoma in humans: no increase detected in surveillance [7]
    A 15-year US postmarketing surveillance study found adult osteosarcoma incidence among teriparatide users no different from the expected background rate. The current US label states that osteosarcoma has been reported post-marketing but an increased risk has not been observed in human observational studies; it carries no boxed warning.
  • Hypercalcaemia, hypersensitivity reactions, cutaneous calcification and urolithiasis risk [8]
    Listed in Warnings and Precautions of the current US label (revised 08/2026), which added hypersensitivity reactions as a recent major change.

04What is unknown

  • Osteosarcoma risk with use beyond 2 years: the US label states data are limited
  • Hip fracture reduction has not been demonstrated in randomised trials (EMA product overview)
  • No fracture-endpoint randomised trial in men; the male indication rests on bone density
  • No adequately powered randomised evidence that it speeds healing of acute fractures
  • Teriparatide is not named on the 2026 WADA Prohibited List; whether anti-doping authorities would treat it under a catch-all clause was not assessed
  • Regulatory status in the UK, Australia and China was not verified from regulator sources for this record

05Product quality

No independent purity results have been published for this compound yet. The purity programme will publish full methods and vendor-named results, passes and failures, once its protocol has had legal review.

06Citations

  1. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis (2001). doi:10.1056/NEJM200105103441904
  2. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial (2018). doi:10.1016/S0140-6736(17)32137-2
  3. The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis (2003). doi:10.1359/jbmr.2003.18.1.9
  4. Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis (2007). doi:10.1056/NEJMoa071408
  5. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures (2010). doi:10.1359/jbmr.090731
  6. Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose. doi:10.1080/01926230490462138
  7. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. doi:10.1002/jbmr.4188
  8. FORTEO (teriparatide injection) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021318Orig1s059lbl.pdf

Every DOI is resolved against Crossref and every NCT number against ClinicalTrials.gov, title for title, before publication. Regulatory sources are cited inline above with a verbatim quote and retrieval date.

07Mechanism

Teriparatide binds the same cell-surface receptors as endogenous parathyroid hormone in bone and kidney; intermittent exposure in clinical trials increased markers of bone formation and bone mineral density.

Mechanism is placed last on purpose: a plausible mechanism is not evidence that a compound works in people.

Reviewed by OSMF research team (AI-assisted, source-verified) on 2026-10-10. Found an error? It goes in the corrections log: report it.